0R15 8539.0 2.1534% 0R1E 8600.0 3.3654% 0M69 None None% 0R2V 190.25 -0.1312% 0QYR 1345.5 2.0871% 0QYP 424.0 0.5931% 0LCV 146.6464 -1.3147% 0RUK None None% 0RYA 1631.0 -0.6094% 0RIH 171.3 0.9131% 0RIH 174.9 2.1016% 0R1O 186.0 9820.0% 0R1O None None% 0QFP None None% 0M2Z 298.3 -0.6495% 0VSO None None% 0R1I None None% 0QZI 474.5 0.6363% 0QZ0 220.0 0.0% 0NZF None None%
Last update at 2024-05-16T16:10:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -39.69600M | -84.93600M | -84.23400M | -76.28200M | -56.67100M |
| Minority interest | - | - | - | - | - |
| Net income | -43.47800M | -84.93600M | -84.23400M | -76.28200M | -56.67100M |
| Selling general administrative | 17.26M | 21.64M | 23.78M | 20.70M | 20.11M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | -28.00100M | -35.72600M | -20.13900M | -48.56600M | - |
| Reconciled depreciation | - | - | - | - | - |
| Ebit | -45.25700M | -57.37000M | -48.50400M | -77.09000M | -58.16600M |
| Ebitda | -42.16400M | -54.12000M | -43.91800M | -69.27100M | - |
| Depreciation and amortization | 3.09M | 3.25M | 4.59M | 7.82M | - |
| Non operating income net other | - | - | - | - | - |
| Operating income | -45.25700M | -57.37000M | -48.50400M | -77.09000M | -58.16600M |
| Other operating expenses | 40.80M | 84.32M | 91.42M | 77.09M | - |
| Interest expense | - | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Tax provision | - | - | - | - | - |
| Interest income | - | - | 2.81M | 0.81M | 1.50M |
| Net interest income | - | - | - | - | - |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 3.78M | - | - | - | - |
| Total revenue | 1.41M | 3.00M | 10.00M | - | 3.00M |
| Total operating expenses | 11.39M | 45.59M | 61.28M | 28.52M | - |
| Cost of revenue | 29.41M | 38.73M | 30.14M | 48.57M | - |
| Total other income expense net | 5.56M | -27.56600M | -35.73000M | 0.81M | - |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | - | - | - | - | - |
| Net income applicable to common shares | -43.47800M | -84.93600M | -84.23400M | -76.28200M | -56.67100M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 64.21M | 79.59M | 151.20M | 223.38M | 174.40M |
| Intangible assets | - | 1.38M | 1.50M | 36.18M | 43.04M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.95M | 8.27M | 2.71M | 3.13M | - |
| Total liab | 37.45M | 37.22M | 48.65M | 44.95M | 40.35M |
| Total stockholder equity | 26.76M | 42.37M | 102.55M | 178.43M | 134.04M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 5.97M | 12.30M | 37.26M | 34.94M | 10.30M |
| Common stock | 0.18M | 1.47M | 0.96M | 0.84M | 0.48M |
| Capital stock | - | - | - | - | - |
| Retained earnings | -695.33600M | -655.64000M | -570.70400M | -486.47000M | -410.18800M |
| Other liab | 23.82M | 4.03M | - | - | 20.00M |
| Good will | - | - | 32.47M | 32.47M | 32.47M |
| Other assets | 0.04M | 0.17M | 1.14M | 1.14M | 0.60M |
| Cash | 14.22M | 32.94M | 12.60M | 129.26M | 18.75M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 7.78M | 16.62M | 41.96M | 38.70M | 20.35M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -14.21700M | -32.93800M | -12.59600M | -129.25800M | - |
| Short term debt | - | - | - | - | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | - | - | 1.43M | - | - |
| Other stockholder equity | 721.92M | 696.54M | 672.29M | 664.06M | - |
| Property plant equipment | 11.07M | 21.74M | 18.35M | 21.20M | 9.44M |
| Total current assets | 53.10M | 56.29M | 97.74M | 132.39M | 88.85M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | 26.76M | 49.99M | 68.58M | 109.79M | 58.54M |
| Short term investments | 37.93M | 12.09M | 82.44M | - | 66.22M |
| Net receivables | 0.19M | 3.00M | - | - | 0.08M |
| Long term debt | - | - | 1.43M | - | - |
| Inventory | - | 0.00000M | - | - | - |
| Accounts payable | 1.81M | 4.33M | 4.70M | 3.76M | 6.12M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | -11.07200M | -23.12600M | -52.32000M | -89.84800M | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 11.07M | 23.13M | 52.32M | 89.85M | - |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | - | 70.21M | -82.37800M | 66.48M | -65.59200M |
| Change to liabilities | -5.49000M | 0.82M | -2.17800M | -1.70700M | 7.96M |
| Total cashflows from investing activities | -23.96400M | 66.06M | -83.71400M | 59.98M | -85.08600M |
| Net borrowings | - | - | 1.76M | 1.76M | 1.76M |
| Total cash from financing activities | 43.17M | 24.86M | 1.94M | 113.90M | 5.48M |
| Change to operating activities | - | -16.08800M | 3.81M | -1.92700M | -1.02700M |
| Net income | -39.69600M | -84.93600M | -84.23400M | -76.28200M | -56.67100M |
| Change in cash | -24.27400M | 25.26M | -116.79700M | 111.06M | -118.72000M |
| Begin period cash flow | 38.83M | 13.57M | 130.37M | 19.31M | - |
| End period cash flow | 14.55M | 38.83M | 13.57M | 130.37M | 19.31M |
| Total cash from operating activities | -43.48300M | -65.66500M | -35.01900M | -62.82000M | -39.11100M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 4.58M | 4.46M | 5.60M | 8.68M | 2.36M |
| Other cashflows from investing activities | - | - | -82.37800M | 66.48M | -65.59200M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | 3.00M | -3.00000M | -3.00000M | 0.08M | 0.03M |
| Sale purchase of stock | - | - | 0.18M | 113.90M | 5.48M |
| Other cashflows from financing activities | 43.17M | 24.86M | 1.94M | 113.90M | -1.45400M |
| Change to netincome | - | 33.07M | 41.98M | 8.34M | 8.24M |
| Capital expenditures | 0.13M | 4.15M | 1.34M | 6.31M | 9.24M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 3.00M | -3.00000M | 1.63M | 0.08M | 6.96M |
| Stock based compensation | 3.05M | 8.92M | 8.19M | 8.24M | - |
| Other non cash items | -14.41500M | 8.89M | 35.43M | -3.53300M | - |
| Free cash flow | -43.61300M | -69.81600M | -36.35500M | -69.12900M | - |
Sector: Industry:
| Company | Change (GBP) | Price (GBP) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) |
|---|---|---|---|---|---|---|
| 0H7R Abeona Therapeutics Inc. |
-0.05 1.06% | 4.66 | - | - | 0.36 | - |
| 0LCV Taiwan Semiconductor Manufacturing Co. Ltd. ADR |
-1.9536 1.31% | 146.65 | 0.20 | - | 0.01 | - |
| 0RIH Alphabet Inc Class A |
1.55 0.91% | 171.30 | - | - | - | - |
| 0M2Z Equinor ASA |
-1.95 0.65% | 298.30 | - | - | - | - |
| 0QZI Facebook Inc. Cl A |
3.00 0.64% | 474.50 | - | - | - | - |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.
1330 Avenue of the Americas, New York, NY, United States, 10019
| Name | Title | Year Born |
|---|---|---|
| Dr. Vishwas Seshadri M.B.A., Ph.D. | Pres, CEO & Director | 1976 |
| Dr. Brendan M. O'Malley J.D., Ph.D. | Sr. VP & Gen. Counsel | 1969 |
| Mr. Joseph Walter Vazzano | Chief Financial Officer | 1984 |
| Mr. Brian Kevany Ph.D. | VP, CTO & Head of Research | NA |
| Mr. Gregory Gin | VP of Investor Relations & Corp. Communications | NA |
| Scott Santiamo | Director of Corp. Communications | NA |
| Ms. Alison Hardgrove | VP of HR | NA |
| Mr. Jon Voss | VP & Head of Quality | 1960 |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
UK 
AU
CA
US
NZ
Please wait processing your request...